Valuation: Replimune Group, Inc.

Market Cap 972M 850M 781M 728M 1.38B 92.56B 1.4B 9.38B 3.64B 45.5B 3.65B 3.57B 157B P/E 2027 *
-5.46x
P/E 2028 * -9.31x
Enterprise Value 955M 835M 767M 715M 1.36B 90.94B 1.38B 9.21B 3.58B 44.7B 3.59B 3.51B 154B EV / Sales 2027 *
28.5x
EV / Sales 2028 * 13.9x
Free-Float
97.44%
Yield 2027 *
-
Yield 2028 * -
1 day+3.21%
1 week-0.43%
Current month+4.61%
1 month+16.03%
3 months+37.69%
6 months+30.11%
Current year+19.14%
1 week 10.97
Extreme 10.97
12.5
1 month 8.25
Extreme 8.25
12.5
Current year 1.5
Extreme 1.5
12.5
1 year 1.5
Extreme 1.5
13.24
3 years 1.5
Extreme 1.5
22.61
5 years 1.5
Extreme 1.5
39.84
10 years 1.5
Extreme 1.5
54.85
Manager TitleAgeSince
Chief Executive Officer 55 2024-03-31
Director of Finance/CFO 46 2023-09-18
Chief Tech/Sci/R&D Officer 60 2022-11-30
Director TitleAgeSince
Chairman 54 2024-03-31
Director/Board Member 66 2017-06-30
Chairman 65 2020-03-31
Date Insider Type Main position Quantity % Market Cap.
05-31Sell

Chief Commercial Officer

-12,000 0.0154%
05-17Sell

Controller/Auditor

-7,894 0.0101%
05-17Sell

Chief Technology Officer

-14,023 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
+3.21%-0.43%+23.19%-47.17% 972M
+1.70%+7.41%+3.12%+8.46% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+11.89%+38.86% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +2.28%+5.65%+73.62%+101.69% 24.66B
Weighted average by Cap. +2.07%+6.52%+90.46%+136.96%

Financials

2027 *2028 *
Net sales 33.54M 29.32M 26.95M 25.12M 47.64M 3.19B 48.37M 324M 126M 1.57B 126M 123M 5.41B 69.91M 61.12M 56.17M 52.35M 99.3M 6.66B 101M 674M 262M 3.27B 262M 257M 11.28B
Net income -205M -180M -165M -154M -292M -19.55B -296M -1.98B -770M -9.61B -771M -754M -33.12B -148M -129M -119M -111M -210M -14.09B -213M -1.43B -555M -6.93B -556M -544M -23.87B
Net Debt -17M -14.86M -13.66M -12.73M -24.15M -1.62B -24.51M -164M -63.74M -796M -63.81M -62.44M -2.74B -
Logo Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Employees
465
Date Price Change Volume
26-07-02 US$11.58 +3.21% 2,844,729
26-07-01 US$11.22 +1.36% 2,975,672
26-06-30 US$11.07 -1.16% 4,327,328
26-06-29 US$11.20 -3.70% 3,737,454
26-06-26 US$11.63 +4.49% 9,985,314
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
11.58USD
Average target price
10.67USD
Spread / Average Target
-7.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REPL Stock